| Creatine phosphokinase MB subgroup | |||||||
| n | <25 [μg/l] | 25 - 49 [μg/l] | 50 - 74 [μg/l] | 75 - 99 [μg/l] | ≥100 [μg/l] | ||
| 414 | (n = 92) | (n = 99) | (n = 77) | (n = 67) | (n = 79) | ||
| Demographics | |||||||
| Age_years (IQR) | 414 | 63 (45 - 83) | 64 (39 - 82) | 65 (38 - 84) | 66 (44 - 80) | 63 (37 - 82) | |
| Males_number (%) | 414 | 77 (84) | 92 (93) | 55 (72) | 45 (67) | 60 (76) | |
| Body-mass-index_kg/m2 (SD) | 411 | 28 (4) | 29 (4) | 28 (6) | 27 (4) | 27 (4) | |
| Preoperative | |||||||
| Smoking_number (%) | 403 | ||||||
| Never | 11 (12) | 27 (28) | 23 (31) | 19 (28) | 21 (29) | ||
| Previous | 50 (55) | 48 (50) | 33 (44) | 34 (51) | 31 (43) | ||
| Active | 30 (33) | 22 (23) | 19 (25) | 14 (21) | 21 (29) | ||
| Ejection fraction_% (SD) | 413 | 51 (9) | 51 (11) | 51 (10) | 54 (12) | 53 (13) | |
| S-creatinin_mmol/l (IQR) | 412 | 96 (68 - 1002) | 97 (25 - 800) | 96 (62 - 192) | 98 (69 - 201) | 97 (70 - 171) | |
| Coexisting_number (%) | |||||||
| Ischemic heart disease | 398 | 33 (36) | 47 (48) | 39 (51) | 34 (55) | 33 (47) | |
| Diabetes mellitus | 414 | 18 (20) | 18 (18) | 14 (18) | 8 (12) | 6 (8) | |
| Chronic obstructive pulmonary disease | 404 | 6 (7) | 1 (1) | 5 (7) | 5 (8) | 5 (7) | |
| Peripheral artery disease | 414 | 15 (16) | 9 (9) | 8 (10) | 3 (5) | 12 (15) | |
| Previous cardiac surgery | 414 | 0 (0) | 6 (6) | 4 (5) | 6 (9) | 8 (10) | |
| Previous percutaneous coronary intervention | 414 | 17 (19) | 20 (20) | 10 (13) | 9 (13) | 10 (13) | |
| Previous myocardial infarction | 407 | 37 (40) | 51 (52) | 35 (46) | 29 (43) | 44 (60) | |
| Medication_number (%) | |||||||
| Lipid | 412 | 80 (87) | 89 (90) | 62 (81) | 41 (62) | 49 (63) | |
| Hypertensive | 411 | 49 (53) | 68 (69) | 43 (56) | 30 (46) | 31 (40) | |
| Beta-blocker | 413 | 62 (67) | 73 (74) | 59 (77) | 49 (73) | 60 (77) | |
| Calcium-antagonist | 413 | 29 (32) | 39 (39) | 29 (38) | 27 (40) | 19 (24) | |
| Angiotensin converting enzyme inhibitor | 414 | 51 (55) | 45 (46) | 32 (42) | 22 (33) | 21 (27) | |